RxDoctor Payments DataLook up a doctor →

Ali El-Mohandes, MD

Interventional Pain Medicine · Hagerstown, MDNPI 1952308827

Payments from drug & device makers

$56,866in general payments, 2019–2025

Across 677 payments — averaging $84.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$26K
  • Stimwave Technologies Incorporated$16K
  • GRT US Holding, Inc.$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Medtronic$2K
  • Spinal Simplicity, LLC$1K
  • plus $8K from 49 others

What the payments were for

  • Consulting fees$16,25029%
  • Speaking & faculty fees$23,72942%
  • Travel & lodging$3,2536%
  • Food & beverage$13,63424%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,866 in reported general payments places this provider in the 90th percentile of 56 interventional pain medicine providers in Maryland.

See all interventional pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$133,164
Medicare patients
236
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate16$8,966
OxycontinOxycodone Hcl12$6,615
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen81$2,050
Oxycodone Hcl108$1,669
Fentanyl16$1,602
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$863
Gabapentin53$788
Morphine Sulfate ErMorphine Sulfate20$581
Tizanidine Hcl41$560
Pregabalin15$337
Tramadol Hcl55$243
Hydromorphone Hcl15$196
Methylprednisolone18$129
Cyclobenzaprine Hcl16$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$857$8,96616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 interventional pain medicine providers in Maryland.

Other interventional pain medicine in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →